TG Therapeutics Management
Management criteria checks 3/4
TG Therapeutics' CEO is Mike Weiss, appointed in Dec 2011, has a tenure of 12.33 years. total yearly compensation is $10.44M, comprised of 8.4% salary and 91.6% bonuses, including company stock and options. directly owns 5.31% of the company’s shares, worth $115.63M. The average tenure of the management team and the board of directors is 12.3 years and 10.4 years respectively.
Key information
Mike Weiss
Chief executive officer
US$10.4m
Total compensation
| CEO salary percentage | 8.4% |
| CEO tenure | 12.3yrs |
| CEO ownership | 5.3% |
| Management average tenure | 12.3yrs |
| Board average tenure | 10.4yrs |
Recent management updates
Recent updates
TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet
Mar 25
TG Therapeutics: Briumvi Growth Story Appears Intact
Mar 01Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Mar 01TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference
Jan 10Some Confidence Is Lacking In TG Therapeutics, Inc.'s (NASDAQ:TGTX) P/S
Jan 04Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?
Nov 24TG Therapeutics, Inc. (NASDAQ:TGTX) Not Flying Under The Radar
Sep 30Upgrade: Analysts Just Made A Stunning Increase To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts
Aug 03Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jul 19Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?
Apr 13Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?
Jan 02TG Therapeutics: Elucidating The Upcoming Binary
Oct 09TG Therapeutics: We Are Just Hanging In There
Sep 21Despite Lacking Profits TG Therapeutics (NASDAQ:TGTX) Seems To Be On Top Of Its Debt
Sep 07TG Therapeutics announces peer-reviewed publication of multiple sclerosis phase 3 trials
Aug 25TG Therapeutics Q2 2022 Earnings Preview
Aug 05TG Therapeutics And Ublituximab: From Icing To Lifeline
Jul 08Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jun 06TG Therapeutics: I May Double Down Again
Apr 18Ublituximab In MS Is The Heart Of TG Therapeutics, And The Heart Is Safe
Feb 08TG Therapeutics: Double Down On Partial Clinical Hold Non-Issue
Jan 28TG Therapeutics: Elucidating The Upcoming Binary Event
Dec 27CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | US$13m |
| Sep 30 2023 | n/a | n/a | -US$26m |
| Jun 30 2023 | n/a | n/a | -US$176m |
| Mar 31 2023 | n/a | n/a | -US$169m |
| Dec 31 2022 | US$10m | US$875k | -US$198m |
| Sep 30 2022 | n/a | n/a | -US$239m |
| Jun 30 2022 | n/a | n/a | -US$288m |
| Mar 31 2022 | n/a | n/a | -US$326m |
| Dec 31 2021 | US$43m | US$1m | -US$348m |
| Sep 30 2021 | n/a | n/a | -US$343m |
| Jun 30 2021 | n/a | n/a | -US$345m |
| Mar 31 2021 | n/a | n/a | -US$319m |
| Dec 31 2020 | US$32m | US$1m | -US$279m |
| Sep 30 2020 | n/a | n/a | -US$231m |
| Jun 30 2020 | n/a | n/a | -US$206m |
| Mar 31 2020 | n/a | n/a | -US$189m |
| Dec 31 2019 | US$13m | US$637k | -US$173m |
| Sep 30 2019 | n/a | n/a | -US$187m |
| Jun 30 2019 | n/a | n/a | -US$159m |
| Mar 31 2019 | n/a | n/a | -US$167m |
| Dec 31 2018 | US$14m | US$656k | -US$173m |
| Sep 30 2018 | n/a | n/a | -US$150m |
| Jun 30 2018 | n/a | n/a | -US$148m |
| Mar 31 2018 | n/a | n/a | -US$132m |
| Dec 31 2017 | US$10m | US$525k | -US$118m |
Compensation vs Market: Mike's total compensation ($USD10.44M) is above average for companies of similar size in the US market ($USD5.57M).
Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.
CEO
Mike Weiss (57 yo)
12.3yrs
Tenure
US$10,435,150
Compensation
Mr. Michael S. Weiss, Esq. J.D. also known as Mike, serves as Director of Urica Therapeutics, Inc. He has been an Executive Chairman of Mustang Bio, Inc. since January 2017 and served as its Interim Presid...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 12.3yrs | US$10.44m | 5.31% $ 115.6m | |
| CFO, Corporate Secretary & Treasurer | 12.3yrs | US$1.97m | 0.44% $ 9.6m | |
| Senior Vice President of Corporate Communications | no data | no data | no data | |
| Chief Commercialization Officer | 5.8yrs | no data | no data |
12.3yrs
Average Tenure
Experienced Management: TGTX's management team is seasoned and experienced (12.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 12.3yrs | US$10.44m | 5.31% $ 115.6m | |
| Lead Independent Director | 12yrs | US$437.50k | 0.14% $ 3.0m | |
| Independent Director | 9.3yrs | US$397.50k | 0.16% $ 3.4m | |
| Independent Director | 11.4yrs | US$395.00k | 0.14% $ 3.1m | |
| Independent Director | 4yrs | US$392.50k | 0.070% $ 1.5m | |
| Independent Director | 8.8yrs | US$395.00k | 0.14% $ 3.1m |
10.4yrs
Average Tenure
57.5yo
Average Age
Experienced Board: TGTX's board of directors are seasoned and experienced ( 10.4 years average tenure).